O ur understanding of inherited breast cancer susceptibility has changed dramatically over the last 5 years, with the discovery of many genes in which mutations influence the risk of developing breast cancer.
These fall into three main groups: genes in which mutations confer a high risk of developing cancer, but where such mutations are rare; uncommon mutations in genes conferring a moderate increase in risk (odds ratios of approximately 2 -4), and common polymorphic variants which each confer only slight risk alterations (odds ratios rarely above 1.2 for variants conferring increased risk). The discovery of these genes and loci was predicated on linkage analysis (for high-risk genes), screening for mutations in candidate genes selected because they were involved in functional pathways related to BRCA1 and BRCA2 function (moderate risk), and genome-wide association studies (low penetrance polymorphisms).
However, with this increased knowledge comes the difficulty of knowing how this information may best be utilized in clinical practice. Other syndromes discussed in this review which may be associated with a moderately increased breast cancer risk include neurofibromatosis type 1 and Nijmegen breakage syndrome mutation carriers, and the slight increase in risk associated with Lynch syndrome is referred to, although the relative increase in breast cancer risk in Lynch syndrome is debated and generally considered to be low, but may vary with the different genes involved.
The common low-penetrance breast cancer susceptibility alleles
The rapid increase in case -control studies 6 utilising single nucleotide polymorphisms has led to an abundance of literature on this subject and has been well summarized by this review. The authors demonstrate clearly that some of these studies currently provide contradictory evidence of the importance of the role of such polymorphisms. However, there is good evidence now that there are up to eight polymorphisms, which are reproducibly found to influence breast cancer risk, particularly the FGFR2 gene. Carriers of two low risk rs2981582 alleles at the FGFR2 locus (frequency 38% of the population) have a relative risk of breast cancer of 0.83 compared with the general population, carriers of one high-risk and one low-risk allele (47%) have a relative risk of 1.05, and carriers of two high-risk alleles (14%) have a relative risk of 1.26. The overall importance of these polymorphisms remains high, because their effect appears to be multiplicative, such that an individual possessing several polymorphisms conferring increased risk may have a significantly increased risk of breast cancer. 3, 7 Many of these polymorphic loci are of unknown function, and the polymorphic site may be outside any functional gene locus. The associated risks with each polymorphism are low, and the five most significant loci described by Easton et al 8 account for only 3.6% of the excess familial breast cancer risk in the European population. Interestingly, the polymorphisms at 10q26 and 5q11, and homozygosity for a variant in RAD51 also affect risk in women who carry mutations in BRCA2, but not in BRCA1 mutation carriers (thought likely to be related to the predominance of oestrogen negative tumours in BRCA1 mutation carriers). However, mutations in CHEK2 appear not to have such an effect, presumably because this gene acts in the same functional pathway as the BRCA1/2 genes, and as these functions are already disrupted in BRCA1/2 mutation carriers, further disruption of this pathway may not have any appreciable additional effect.
The role in the overall causation of breast cancer of variants of uncertain pathogenicity in BRCA1, BRCA2 in the causation of breast cancer susceptibility is uncertain. 7 Clearly, there may be many more low penetrance susceptibility polymorphisms, 9 which may differ in frequency in different populations. Commercial companies have rapidly seized upon literature describing low penetrance polymorphisms in breast cancer and have adapted them for use in commercially provided susceptibility testing. The keen media interest in this kind of testing has demonstrated the potential appetite of the general public for personalized genetic testing. What is less clear is whether the implications of genetic screening are fully understood, in terms of risk, the effects of lifestyle modification, and service provision. They are based on the best available state of knowledge of these low risk polymorphisms, which, however, is evolving. This has already lead to a situation where individuals undergo this type of screening, and may then present to their general practitioners and genetic clinics, concerned because they possess a susceptibility polymorphism which increases their cancer risk only marginally.
The current difficulty in determining the ideal breast cancer susceptibility test is based on constantly evolving genetic knowledge. Lifestyle factors, such as smoking, age at menarche and menopause, childbearing, breast feeding, and use of hormonal contraception and HRT are still very important influences on the development of breast cancer and should not be underestimated. The identification of these highly variable polymorphisms is a paradigm shift in our understanding of the pieces of the susceptibility jigsaw, but at the current state of knowledge, how they all fit together and what implications they have for counselling is still uncertain until we fully understand how all the elements of susceptibility, both genetic and environmental, interact'
